


In the Claims

Claim 1 (Original): A growth factor binding compound comprising a plurality of peptide loops attached to a non-peptide organic scaffold.


Claim 2 (Original): The compound of claim 1, in which said scaffold is a calixarene or (C₈-C₁₂)aryl.

Claim 3 (Original): The compound of claim 1, in which said peptide loop comprises a tetrapeptide.

Claim 4 (Previously presented): A growth factor binding compound, of the general structure:



wherein R is n-butyl, n-propyl, benzyl, (C₁-C₁₂) alkyl, (C₇-C₁₈) aralkyl, (C₆-C₁₈) aryl, (C₁-C₁₂) alkenyl, (C₇-C₁₈) aralkenyl, (C₁-C₁₂) alkylether, and X are independently cyclic peptide loops of the general structure:



wherein R_1 , R_2 , R_3 , and R_4 are each amino acid side chains that define a tetrapeptide sequence, wherein said tetrapeptide is covalently attached at the amino and carboxy termini of said tetrapeptide to a 3-aminomethyl-5-aminobenzamide linking group, and wherein said tetrapeptide sequence is selected from the group consisting of GDFD (SEQ ID NO. 1), GDDD (SEQ ID NO. 2), D-ADGD (SEQ ID NO. 3), GDLD (SEQ ID NO. 4), GDAD (SEQ ID NO. 5), GDGY (SEQ ID NO. 6), ADGD (SEQ ID NO. 7), GDSD (SEQ ID NO. 8), GKGF (SEQ ID NO. 9), GK GK (SEQ ID NO. 10), GDND (SEQ ID NO. 11), PDGD (SEQ ID NO. 12), GDDG (SEQ ID NO. 13), and GDDY (SEQ ID NO. 14).

Claim 5 (Previously presented): The compound of claim 4, in which said growth factor is a platelet derived growth factor, and wherein said tetrapeptide sequence is GDGY (SEQ ID NO. 6).

Claim 6 (Currently amended): A composition comprising ~~a pharmaceutically acceptable salt of the compound of claim 1 in the compound of claim 1, or a pharmaceutically acceptable salt thereof,~~ and a pharmaceutically acceptable carrier.

Claim 7 (Currently amended): A method of treatment of a patient subject having a disease comprising excess cellular proliferation, excess angiogenesis, a tumor, or a combination thereof, wherein said method comprises administering to the subject an effective amount of the composition of claim 6 growth factor binding compound of claim 1, or a pharmaceutically acceptable salt thereof.

Claim 8 (Original): The method as in claim 7, wherein said tumor expresses elevated amounts of platelet derived growth factor.

Claim 9 (Original): A method for measuring the amount of a growth factor in a sample, comprising:

obtaining a fluid sample suspected of containing a growth factor;
contacting said sample with a compound of claim 1 that binds said growth factor; and
detecting the binding of said growth factor to said compound.

Claim 10 (Original): The method of claim 9, wherein said compound is radiolabeled, fluorescently labeled, or both.

Claim 11 (Original): The method as in claim 9, wherein said compound is attached to a surface.

Claim 12 (Original): A method for the delayed release of a growth factor in a patient, comprising administering to said patient a stoichiometric complex of said growth factor and a compound of claim 1.

Claim 13 (Currently amended): A method of treatment of a subject suffering from, or at risk of, restenosis, comprising administering to the subject an effective amount of the ~~composition of claim 6~~ growth factor binding compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the effective amount inhibits, prevents or ameliorates restenosis.

Claim 14 (Original): The method of claim 13 wherein the restenosis results from balloon angioplasty, insertion of a vascular stent, or resection of a blood vessel.

Claim 15 (Previously presented): The compound of claim 4 wherein said growth factor is vascular endothelial growth factor and wherein said tetrapeptide sequence is GKGK (SEQ ID NO. 10), GDGY (SEQ ID NO. 6), or functionally related derivatives thereof.

Claim 16 (Previously presented): The compound of claim 4 wherein said growth factor is acidic fibroblast growth factor and wherein said tetrapeptide sequence is GDDD (SEQ ID NO. 2), GKGK (SEQ ID NO. 10), GDDG (SEQ ID NO. 13), GDGY (SEQ ID NO. 6), or functionally related derivatives thereof.

Claim 17 (Previously presented): The compound of claim 4 wherein said growth factor is insulin-like growth factor-1 and wherein said tetrapeptide sequence is GDDG (SEQ ID NO. 13) or functionally related derivatives thereof.

Claim 18 (New): The method of claim 7, wherein said administering comprises administering the growth factor binding compound of claim 4, or a pharmaceutically acceptable salt thereof, to the subject.

Claim 19 (New): The method of claim 7, wherein said administering comprises administering the composition of claim 6 to the subject.

6

Docket No. USF-T141X
Serial No. 09/811,945

Claim 20 (New): The method of claim 13, wherein said administering comprises administering the growth factor binding compound of claim 4, or a pharmaceutically acceptable salt thereof, to the subject.

Claim 21 (New): The method of claim 13, wherein said administering comprises administering the composition of claim 6 to the subject.

J:\USPT141X\Amend-Resp\Filection2.doc\DNB/mv